World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , 

World Journal of Pharmaceutical
and Medical Research

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 4.103

ICV : 78.6

Abstract

A STUDY ON DERMATOLOGICAL COMORBIDITIES IN PSORIASIS

Soorya Baskaran, Dr. Jayakar Thomas* and Kovi Sneha

ABSTRACT

Background: Psoriasis is an immune mediated inflammatory disorder which occurs in a genetically predisposed individual. It commonly affects the skin, joint, and nail. Multiple studies have reported the association of systemic co-morbidities with psoriasis. Only a few studies have reported the association of other dermatological disorders with psoriasis. This study is done to find the incidence of dermatological co-morbidities in patients with psoriasis. Objective: This study attempts to find out the incidence of dermatological co-morbities in psoriasis patients. Patients and Methods: Hundred patients with psoriasis were included in the study. All the patients were subjected to complete history taking and physical and dermatological examination. Results: In our study about 60% of patients show associated co-morbidities, commonest co-morbidities was malaria rubra (15%), acanthosis nigricans (15%), followed by dermatosis papulosa nigrans (13.3%), androgenetic alopecia (10%), seborrheic keratosis (6.67%), paraphenylene diamine dermatitis (6.67%), dermatophytosis (5%) and others. The presence of multiple co-morbidities was noted in many patients. Conclusion: Dermatological co-morbidities in psoriasis should also be screened and managed along with systemic co-morbidities. Large scale cohort studies are needed to assess the incidence and pathogenesis of dermatological conditions associated with psoriasis.

[Full Text Article]

Powered By WJPMR | All Right Reserved

WJPMR